Hepatitis C virus infection and organ transplantation
In recent years,rapid progress has been made in strategies for the prevention and treatment of hepatitis C virus(HCV)in organ transplant candidates and recipients,and although HCV infections no longer threaten transplantation outcomes in liver or non-hepatic solid organ transplantation,they remain a focus of research.Since hepatitis C is still a leading cause of death worldwide due to decompensated cirrhosis,liver failure,and hepatocellular carcinoma,appropriate organ transplantation is needed to improve survival rate and quality of life.With the increase in HCV-positive solid organ donors in recent years and the fact that the demand for organs still greatly exceeds organ supply,as well as the development of direct-acting antiviral agents,transplantation of HCV-viraemic organs into HCV-naïve recipients will significantly increase transplantation rates and reduce waitlist mortality.The efficacy of current HCV therapies has created an important opportunity to improve the survival rate of patients with end-organ failure by enhancing access to organ transplantation and reducing waitlist mortality.
国家科技期刊平台
NSTL
万方数据
